Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone add-on for negative symptoms in chronic schizophrenia
IRCT20090117001556N159Phase 3Completed
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rosiglitazone in schizophrenia (2 arms), sponsored by University of Social Welfare and Rehabilitation Sciences. Primary endpoint: Severity of schizophrenia. Started Sep 2024; status: completed.
02
Drugs
rosiglitazone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20090117001556N159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N159.